ADC Therapeutics SA
ADCT3.120USD
-0.160-4.88%
Fechamento 07/28, 16:00（ET）Cotações atrasadas em 15 min
309.44MValor de mercado
PerdaP/L TTM
Mais detalhes de ADC Therapeutics SA Empresa
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Informações da empresa
Código da empresaADCT
Nome da EmpresaADC Therapeutics SA
Data de listagemMay 15, 2020
Fundado em2011
CEOMr. Ameet Mallik
Número de funcionários263
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 15
EndereçoBiopole
CidadeEPALINGES
Bolsa de valoresNYSE Consolidated
PaísSwitzerland
Código postal1066
Telefone41216530200
Sitehttps://adctherapeutics.com/
Código da empresaADCT
Data de listagemMay 15, 2020
Fundado em2011
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
+1.60%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
1.55M
-1.70%
Mr. Mohamed Zaki
Mr. Mohamed Zaki
Chief Medical Officer
Chief Medical Officer
642.33K
+50.70%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
404.81K
+0.52%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
361.04K
-11.63%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
180.50K
+26.54%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Independent Director
Non-Executive Independent Director
134.98K
+38.35%
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
99.40K
+38.06%
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Non-Executive Independent Director
Non-Executive Independent Director
55.26K
+98.35%
Dr. Tyrell J. Rivers, Ph.D.
Dr. Tyrell J. Rivers, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
+1.60%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
1.55M
-1.70%
Mr. Mohamed Zaki
Mr. Mohamed Zaki
Chief Medical Officer
Chief Medical Officer
642.33K
+50.70%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
404.81K
+0.52%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
361.04K
-11.63%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
180.50K
+26.54%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qui, 19 de jun
Atualizado em: qui, 19 de jun
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Redmile Group, LLC
15.80%
Prosight Capital
9.62%
HPWH TH AG
8.74%
Point72 Asset Management, L.P.
7.90%
OrbiMed Advisors, LLC
6.02%
Other
51.92%
Investidores
Investidores
Proporção
Redmile Group, LLC
15.80%
Prosight Capital
9.62%
HPWH TH AG
8.74%
Point72 Asset Management, L.P.
7.90%
OrbiMed Advisors, LLC
6.02%
Other
51.92%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
26.07%
Hedge Fund
18.79%
Corporation
15.04%
Investment Advisor
7.91%
Research Firm
7.20%
Individual Investor
6.59%
Private Equity
6.02%
Bank and Trust
0.83%
Insurance Company
0.02%
Other
11.53%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
208
88.44M
89.17%
-13.33M
2025Q1
217
80.51M
81.56%
-23.93M
2024Q4
219
81.03M
83.80%
-19.29M
2024Q3
223
79.78M
82.57%
-21.86M
2024Q2
215
76.61M
81.35%
-7.96M
2024Q1
177
59.13M
71.30%
-27.56M
2023Q4
169
58.32M
71.49%
-25.86M
2023Q3
180
68.48M
85.02%
-18.63M
2023Q2
182
74.11M
92.00%
-12.88M
2023Q1
185
75.45M
93.66%
-4.11M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Redmile Group, LLC
15.67M
15.8%
--
--
Mar 31, 2025
Prosight Capital
9.54M
9.62%
+28.00K
+0.29%
Mar 31, 2025
HPWH TH AG
8.67M
8.74%
-1.12M
-11.42%
May 15, 2025
Point72 Asset Management, L.P.
7.83M
7.9%
+7.83M
--
Jun 16, 2025
OrbiMed Advisors, LLC
5.97M
6.02%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.50M
4.54%
-88.38K
-1.93%
Mar 31, 2025
Oaktree Capital Management, L.P.
4.02M
4.05%
+4.02M
--
Apr 25, 2024
AstraZeneca (UK) Ltd.
4.01M
4.04%
--
--
Dec 31, 2023
Morgan Stanley & Co. LLC
2.96M
2.98%
-968.19K
-24.66%
Mar 31, 2025
Auven Therapeutics General LP
2.23M
2.25%
-4.10M
-64.75%
Apr 23, 2024
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
iShares Micro-Cap ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
iShares Biotechnology ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
Ver Mais
iShares Micro-Cap ETF
Proporção0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0.02%
iShares Biotechnology ETF
Proporção0.02%
ProShares UltraPro Russell2000
Proporção0.01%
ProShares Hedge Replication ETF
Proporção0.01%
Proshares Ultra Russell 2000
Proporção0.01%
iShares Russell 2000 Growth ETF
Proporção0.01%
iShares Russell 2000 Value ETF
Proporção0.01%
Global X Russell 2000 ETF
Proporção0.01%
iShares Russell 2000 ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
